Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the introduction of the severity modifier by NICE in 2022 on the provision of life-extending treatment to those with incurable secondary breast cancer.

The National Institute for Health and Care Excellence (NICE) has been monitoring the impact of the severity modifier since it was implemented in 2022. Data up to March 2025 shows that the proportion of positive cancer recommendations is higher with the severity modifier (85%) than with the end-of-life modifier it replaced (75%). The proportion of positive recommendations for advanced cancer treatments is also higher with the severity modifier (81% compared to 69% with the end-of-life modifier).

Since January 2022, NICE has recommended all but one of the treatments for breast cancer that it has assessed. This includes treatments for advanced breast cancer (such as Truqap and Korserdu), which are now available to eligible NHS patients.

The severity modifier is therefore working as intended and there are currently no plans to adjust or change it in the near future. However, NICE has commissioned research on people’s attitudes to how the severity modifier should be applied that will inform future reviews of NICE’s methods.